骶神经调节与A型肉毒毒素治疗难治性急迫性尿失禁的成本效益:ROSETTA随机试验结果
ROSETTA随机试验对386名难治性急迫性尿失禁女性进行前瞻性经济评估,比较两阶段骶神经调节与200单位A型肉毒毒素注射。2年时骶神经调节费用显著更高(35680美元 vs 7460美元),但疗效无差异;5年费用差异持续。骶神经调节相对A型肉毒毒素在所有意愿支付阈值下具有成本效益的概率均较低。
要点
- 骶神经调节2年费用显著高于A型肉毒毒素(35680 vs 7460美元)
- 两种治疗在减少急迫性尿失禁发作和QALYs上无显著差异
- 骶神经调节在常规意愿支付阈值下不具有成本效益
核心结论
- 尽管两种治疗均有效,但骶神经调节的高成本使其相对于200单位A型肉毒毒素治疗急迫性尿失禁不具备良好价值。
研究设计与样本
- 前瞻性经济评估与ROSETTA随机试验同步进行,纳入386名3天日记中急迫性尿失禁发作≥6次的女性。
- 分析从医疗保健系统角度进行,主要进行2年内的试验内分析,次要进行5年决策分析。
- 成本以2018年美元计,效果以质量调整生命年(QALYs)和每日急迫性尿失禁发作减少量衡量。
主要发现
- 2年成本骶神经调节高于A型肉毒毒素(35680美元[95%CI 33,920-37,440] vs 7460美元[95%CI 5,780-9,150],p<0.01)。
- 5年成本差异持续(36550美元[95%CI 34,787-38,309] vs 12020美元[95%CI 10,330-13,700],p<0.01)。
- 2年时每日急迫性尿失禁发作减少量无差异(-3.00[95%CI -3.38至-2.62] vs -3.12[95%CI -3.48至-2.76],p=0.66)。
- 2年时QALYs无差异(1.39[95%CI 1.34-1.44] vs 1.41[95%CI 1.36-1.45],p=0.60)。
- 骶神经调节具有成本效益的概率在2年时所有低于580,000美元/QALY的意愿支付阈值下均小于0.025,5年时低于204,000美元/QALY阈值下均小于0.025。
关键数值与推荐
- 2年成本:骶神经调节35680美元(95%CI 33,920-37,440) vs A型肉毒毒素7460美元(95%CI 5,780-9,150),p<0.01。
- 5年成本:骶神经调节36550美元(95%CI 34,787-38,309) vs A型肉毒毒素12020美元(95%CI 10,330-13,700),p<0.01。
- 2年每日急迫性尿失禁发作减少:骶神经调节-3.00(95%CI -3.38至-2.62) vs A型肉毒毒素-3.12(95%CI -3.48至-2.76),p=0.66。
- 2年QALYs:骶神经调节1.39(95%CI 1.34-1.44) vs A型肉毒毒素1.41(95%CI 1.36-1.45),p=0.60。
- 成本效益概率:2年时意愿支付阈值低于580,000美元/QALY、5年时低于204,000美元/QALY,骶神经调节具有成本效益的概率均<0.025。
临床怎么用
- 对于难治性急迫性尿失禁女性,A型肉毒毒素注射在成本效益上优于骶神经调节。
- 临床决策可优先考虑A型肉毒毒素,尤其在意愿支付阈值较低的场景。
- 骶神经调节虽有效,但高昂费用限制其作为一线成本效益选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Sacral neuromodulation and intradetrusor onabotulinumtoxinA injection are therapies for refractory urgency urinary incontinence. Sacral neuromodulation involves surgical implantation of a device that can last 4 to 6 years while onabotulinumtoxinA therapy involves serial office injections. We assessed the cost-effectiveness of 2-stage implantation sacral neuromodulation vs 200 units onabotulinumtoxinA for the treatment of urgency urinary incontinence. MATERIALS AND METHODS: Prospective economic evaluation was performed concurrent with the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment) randomized trial of 386 women with 6 or more urgency urinary incontinence episodes on a 3-day diary. Analysis is from the health care system perspective with primary within-trial analysis for 2 years and secondary 5-year decision analysis. Costs are in 2018 U.S. dollars. Effectiveness was measured in quality adjusted life-years (QALYs) and reductions in urgency urinary incontinence episodes per day. We generated incremental cost-effectiveness ratios and cost-effectiveness acceptability curves. RESULTS: Two-year costs were higher for sacral neuromodulation than for onabotulinumtoxinA ($35,680 [95% CI 33,920-37,440] vs $7,460 [95% CI 5,780-9,150], p <0.01), persisting through 5 years ($36,550 [95% CI 34,787-38,309] vs $12,020 [95% CI 10,330-13,700], p <0.01). At 2 years there were no differences in mean reduction in urgency urinary incontinence episodes per day (-3.00 [95% CI -3.38 - -2.62] vs -3.12 [95% CI -3.48 - -2.76], p=0.66) or QALYs (1.39 [95% CI 1.34-1.44] vs 1.41 [95% CI 1.36-1.45], p=0.60). The probability that sacral neuromodulation is cost-effective relative to onabotulinumtoxinA is less than 0.025 for all willingness to pay values below $580,000 per QALY at 2 years and $204,000 per QALY at 5 years. CONCLUSIONS: Although both treatments were effective, the high cost of sacral neuromodulation is not good value for treating urgency urinary incontinence compared to 200 units onabotulinumtoxinA.
引用
- Harvie HS, Amundsen CL, Neuwahl SJ, et al. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial. J Urol. 2019. PMID: 31738113. doi:10.1097/JU.0000000000000656
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。